Cited by 3,140Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; the references it cites are not checked yet.

Second consensus statement on the diagnosis of multiple system atrophy

Open access

Abstract

BACKGROUND: A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here. METHODS: Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology. RESULTS: The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS alpha-synuclein-positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality. CONCLUSIONS: These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.

Overview

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000324625.00404.15

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists haven’t been fetched yet

References 57 · Cited by 3,140

Metadata

Authors
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., & Vidailhet, M.
Affiliations
  • Mayo Clinic (US)
  • AFFILIATIONS From the Departments of Neurology, University of Michigan (S.G.), Ann Arbor, MI; Medical University of Innsbruck (G.K.W., W.P., K.S.), Austria; Mayo Clinic Rochester (P.A.L., P.S), Minnesota; and University Hospital Bonn (T.K.), Germany; Hammersmith Hospital and Department of Clinical Neuroscience (D.B.), Imperial College London, UK; Neurovascular Medicine (Pickering) Unit Faculty of Medicine (C.J.M.), Imperial College London, UK; Department of Pathology and Laboratory Medicine (J.Q.T.)...
Venue
Neurology
Published
2008-08-26
Volume
71
Issue
9
Pages
670-676
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2155299862
Cited by
3,140
References
57
Citations by year
2026: 98 · 2025: 163 · 2024: 209 · 2023: 213 · 2022: 294 · 2021: 268 · 2020: 277 · 2019: 226 · 2018: 191 · 2017: 192 · 2016: 174 · 2015: 170 · 2014: 144 · 2013: 142 · 2012: 107
FWCI
48.77
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Scopus (Elsevier) (submittedVersion)
Funders
  • National Institutes of Health (1r13ns055459-01)
  • National Institute of Neurological Disorders and Stroke (P50NS053488, 1 R13 NS055459)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
multiple system atrophy, diagnostic criteria, alpha-synuclein, glial cytoplasmic inclusions, autonomic dysfunction, parkinsonism, cerebellar ataxia, striatonigral degeneration, olivopontocerebellar degeneration, neuroimaging, neuropathology
MeSH terms
Autonomic Nervous System Diseases, Basal Ganglia, Brain, Inclusion Bodies, Cerebellar Ataxia, Cerebellum, Diagnosis, Differential, Multiple System Atrophy, Parkinsonian Disorders, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review